|
September 26, 2022 |
AAV5 DetectCDx™ Kit Is First ARUP Test Developed to Support a New Therapy The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe. |
NanoSpot.ai’s agreement with the Greek company Opto enables the commercialization and distribution in Europe of NanoSpot.ai’s line of antibody tests, including the SARS-CoV-2 test pictured here. |
September 14, 2022 |
NanoSpot.ai Announces Partnership With Opto to Commercialize SARS-CoV-2 Antibody Test in NanoSpot.ai’s European commercialization agreement is the first for an antibody test originally developed through an ARUP/University of Utah/Techcyte partnership. |
|
July 25, 2022 |
ARUP’s New Monkeypox Test Can Be Performed on More Specimen Types on High-Throughput Instruments ARUP has launched a new, in-house test to detect the DNA of orthopoxviruses, including monkeypox. |
From the left, Tracy George, MD, Jonathan Genzen, MD, PhD, and Adam Barker, PhD, all have gained new responsibilities as part of a strategic alignment of executive responsibilities at ARUP. |
May 9, 2022 |
New Executive Appointments Position ARUP Laboratories for Future Growth Jonathan Genzen, MD, PhD, has been named chief medical officer and Adam Barker, PhD, has been named chief operations officer as part of a realignment of executive responsibilities. |
|
April 28, 2022 |
ARUP Named to Forbes’ List of America’s Best Employers for Diversity for 2022 ARUP Laboratories’ commitment to creating a supportive and satisfying work environment for employees has earned it a place on Forbes magazine’s list of America’s Best Employers for Diversity. |
|
March 1, 2022 |
ARUP Renames Consulting Team as ARUP Healthcare Advisory Services ARUP Laboratories has renamed its expert team of healthcare consultants as ARUP Healthcare Advisory Services. The new name better reflects the broad service offerings the team can provide. |

























